|Merger of GPC Biotech AG into Agennix AG Closes|
Conference call scheduled to provide corporate update on November 6 at 8:00 AM ET/14:00 CET
Martinsried/Munich (Germany), Princeton, N.J. and Houston, TX, November 5, 2009 – Agennix AG today announced that the merger of GPC Biotech AG into Agennix AG is now completed.
Friedrich von Bohlen und Halbach, Ph.D., Chief Executive Officer of Agennix AG, said: “I am very excited about the promise that the new company holds. Our lead program, talactoferrin, is in two Phase 3 trials for non-small cell lung cancer, an area of major unmet medical need. Agennix has an experienced team that combines the best strengths of the individual merger parties. We are focused on advancing talactoferrin and our other development programs, finding the right development and commercialization partners and ensuring we secure sufficient funding to do this effectively.”
The merger was registered today in the commercial register of Agennix AG (ISIN DE000A1A6XX4; Frankfurt Stock Exchange, Prime Standard; previously diagennix GmbH). With the registration of the merger, GPC Biotech AG (ISIN DE0005851505; Frankfurt Stock Exchange, Prime Standard) ceased to exist as a separate legal entity.
The former shareholders of GPC Biotech AG are now shareholders of Agennix AG. The Deutsche Boerse is suspending trading in the GPC Biotech AG shares. Later today, the Frankfurt Stock Exchange is expected to approve the admission of shares of Agennix AG for trading. Trading of the shares of Agennix AG is expected to begin on Friday, November 6, 2009, under the symbol AGX.
As previously reported, GPC Biotech shareholders will receive one ordinary share of Agennix AG for every five shares of GPC Biotech AG, with any remaining fraction to be settled in cash. The share exchange will be settled through the book entry facilities of Clearstream Banking AG, Frankfurt am Main. Shareholders do not need to take any action themselves. As of today, Agennix AG has 18,703,371 shares issued and outstanding.
Agennix AG has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey, USA; and Houston, Texas, USA. The Company is registered in Heidelberg, Germany. The Company currently has approximately 60 employees. The Management Board consists of three members: Friedrich von Bohlen und Halbach, Ph.D., Chief Executive Officer (interim); Torsten Hombeck, Ph.D., Chief Financial Officer; and Rajesh Malik, M.D., Chief Medical Officer.
The Supervisory Board has six members: Christof Hettich, L.L.D. (Chairman); Frank Young, M.D., Ph.D. (Vice Chairman); Juergen Drews, M.D., Ph.D.; Bernd Seizinger, M.D., Ph.D.; James Weaver; and Robert van Leen, Ph.D.
Conference call scheduled
Agennix AG will hold a conference call on Friday, November 6, 2009 at 8 AM ET/14:00 CET to provide a business update. Participants may listen via live webcast, accessible through the Agennix Web site at www.agennix.com, or via telephone. A replay will be available on the Web site following the live event. The call will be conducted in English. The dial-in numbers for the call are as follows:
Participants from Europe: 0049 (0) 69 667775756
0044 (0) 20 3003 2666
Participants from the U.S.: 1-646-843-4608
Please dial in 10 minutes before the beginning of the meeting.
Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies. The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
For further information, please contact:
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 713 552 1091 or +1 609 524 5884
Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0
Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams, Vice President
Phone: +44 207 936 9325